Clinical Trial

A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intracerebroventricular GC1123 in patients with MPS Ⅱ who have central nervous system involvement and are receiving treatment with intravenous drug
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-06-13; most recent amendment 2024-10-13.
Status change: Recruiting → Active, Not Recruiting 2024-10-10
Status change: Not Yet Recruiting → Recruiting 2022-10-14
Trial Details
NCT Number NCT05422482
Lead Sponsor GC Biopharma Corp
Conditions Mucopolysaccharidosis II, Hunter Syndrome
Enrollment 12 participants
Start Date 2022-09-20
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2024-10-15